Opus Genetics is committed to building an innovative, efficient and sustainable clinical-stage ophthalmic biopharmaceutical company leading the development of transformative gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders.
“Opus Genetics has created a compelling pipeline of transformative therapies for patients with inherited retinal diseases, with promising early data. This is an opportunity to advance these treatments quickly. We are excited to bring together a world-class leadership team with deep expertise in the development of potentially groundbreaking gene therapies. We look forward to continuing our progress, creating value and improving outcomes for patients together.”
–George Magrath, MD, CEO, Opus Genetics
